Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

Mr. Shah Coherent Market Insights Pvt. Ltd. + 12524771362 email us here Visit us on social media: LinkedIn Facebook X ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety and promising objective response rates in patients with few treatment choices ...

The electronic health records market is experiencing robust growth, primarily driven by the increasing incidence of chronic diseases that require ong ...

CEO Jensen Huang said quantum computing is at an inflection point, sparking a premarket rally in quantum stocks after he ...

Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. Antares is a spin ...

编者按：近日，Arvinas和辉瑞（Pfizer）公司宣布已为其联合开发的明星PROTAC分子vepdegestrant向美国食品药品监督管理局（FDA）提交新药申请（NDA），用于治疗既往接受过内分泌治疗的雌激素受体阳性（ER+）/人表皮生长因子受体2阴性（HER2-）、ESR1突变的晚期或转移性乳腺癌患者。根据新闻稿，若获批，vepdegestrant将成为 ...